Skip to main content
Back
Activeted-496840-2026

Non-exclusive rebate agreement for the active ingredient Brivaracetam (ATC N03AX23)

Non-exclusive rebate agreement for the active ingredient Brivaracetam (ATC N03AX23): Conclusion of a framework agreement for pharmaceutical companies under equal conditions, with a term from 01.09.2026 to 31.08.2028 and an extension option of 1x12 months. Submission of documents (offer letter, recognized contract with rebates, completed annexes 1 and 2, annex 2 as an Excel file) is via email to openhouse@dak.de. For a contract start on 01.09.2026, documents must be submitted by the 5th of the preceding month; later entries on the 1st or 15th of the following month require submission by the 5th of the preceding month. The procedure automatically ends upon the entry into force of an exclusive contract; further items as per the tender documents.

View original source

CONTRACTING AUTHORITY

Name

DAK-Gesundheit

City

Hamburg

Country

DE

Website

CLASSIFICATION

Procedure Type

Open Procedure

Contract Type

Supplies

Main CPV

33600000, Pharmaceutical products.

ADDITIONAL DETAILS

EU Funded

Yes

Suitable for SMEs

No

Electronic Submission

Required

Legal Basis

32014L0024

DEADLINES & TIMELINE

Submission Deadline

1067 days remaining

(LOT-0001)

Published

Download tender documentsDemo required

TENDER DOCUMENTS

Portal — LOT-0001

NON-RESTRICTED-DOCUMENT

Demo required

TED HTML — 496840-2026

HTML

Demo required

TED PDF — 496840-2026

PDF

Demo required

TED XML — 496840-2026

XML

Demo required
1067 days remaining

Similar Tenders

Explore CPV 33

Carpentry Work for Hamburg Headquarters and Bad Segeberg Academy

Carpentry work: Framework agreement for the headquarters in Hamburg and the academy in Bad Segeberg.

DAK-Gesundheit

·Hamburg
Deadline:August 31, 2026

Drywall works for DAK-Gesundheit Headquarters and Academy

Drywall works for the DAK-Gesundheit headquarters in Hamburg and the academy in Bad Segeberg.

DAK-Gesundheit

·Hamburg
Deadline:August 27, 2026

Non-exclusive discount agreement for Oxybutynin (PFT dosage form)

Non-exclusive discount agreement for the active ingredient Oxybutynin (PFT dosage form only), ATC G04BD04: Contract period from 01.09.2026 to 31.08.2028, with one extension option of 1x12 months. Any pharmaceutical company can conclude a framework agreement at any time under the same conditions. Required documents include a letter of offer, acceptance of the contractual terms and discounts, and completed Annexes 1 and 2, in which the medicines containing the active ingredient must be entered. Documents must be submitted via email to openhouse@dak.de, with Annex 2 to be sent as an Excel file. For a contract start on 01.09.2026, documents must be submitted by the 5th of the preceding month. Later entries are possible at any time; for an entry on the 1st or 15th of the following month, documents must be submitted by the 5th of the preceding month. further items as per the tender documents.

DAK-Gesundheit

·Hamburg
Deadline:July 05, 2029

Non-exclusive discount agreement for Olanzapine (TRS dosage form), ATC N05AH03

Conclusion of non-exclusive discount agreements for the active ingredient Olanzapine (TRS dosage form only), ATC N05AH03. Any pharmaceutical company can conclude a framework agreement under the same conditions during the contract term. The contract term begins on 01.09.2026 and ends on 31.08.2028, with an extension option of 1x12 months. For contract conclusion or later accession, an offer letter, acknowledgment of contractual terms and discounts, and completed Annexes 1 and 2 (Excel file) must be submitted via email to openhouse@dak.de. For accession on 01.09.2026 or on the 1st or 15th of a subsequent month, documents must be submitted by the 5th of the preceding month. This procedure is not subject to cartel procurement law.

DAK-Gesundheit

·Hamburg
Deadline:July 05, 2029

Find matching tenders automatically

With Patterno-HIT, receive relevant tenders daily, automatically filtered to your company profile.

Book Demo Now